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Abstract
Background: Symptomatic disc displacement (DD) of the temporomandibular joint 
(TMJ) may cause pain and limited mouth opening. The aetiopathogenesis is obscure 
and probably complex, which makes the diagnostic classification crude and mainly 
based on clinical criteria rather than disease mechanisms, and tissue characteristics.
Objectives: The study aim was to characterise and quantify synovial tissue in DD, 
where specific cytokine patterns might serve as potential biomarkers.
Methods: An observational cohort study was performed harvesting synovial tis-
sue from 63 patients: 44 with DD without reduction (DDwoR) and 19 with DD with 
reduction (DDwR). DDwoR was subdivided depending on type of onset (sudden, 
n = 17; delayed, n = 27), and DDwR served as the control group. Proteins were ex-
tracted from tissue samples and investigated in a multi-analytic profiling system.
Results: DDwoR patients had significantly higher concentrations in 12 out of 28 ana-
lysed cytokines compared to DDwR. In the same statistical model, significantly lower 
concentrations of interferon gamma-induced protein (IP) 10, osteoprotegerin (OPG) 
and RANTES were detected in DDwoR patients. Women showed significantly higher 
concentrations of epidermal growth factor and interleukin (IL) 1ra compared to men. 
DDwoR with sudden onset had significant higher concentrations of bone morphoge-
netic protein 4, eotaxin and IL-8 compared to DDwoR with delayed onset.
Conclusions: Characterising the biomarker panel for TMJ conditions may serve as 
suggestible targets for disease classification and novel treatment options. The sig-
nificantly lower concentrations of IP-10, OPG and RANTES could be proposed as 
putative markers for the separation of the studied conditions to other TMJ diseases.
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1  | INTRODUC TION
Disc displacement (DD) of the temporomandibular joint (TMJ) is 
common affecting 15 to 31% of investigated populations.1-3 Few in-
dividuals with DD suffer to such an extent that they need treatment, 
implying that in most cases, a displaced disc needs a cofactor, cata-
lyst or interactor to give rise to symptomatic arthralgia, arthritis and/
or limited mouth opening. However, patients with TMJ complaints 
often show DD.2
Treatment of symptomatic DD is primarily conservative, such as 
orthotic splint, medication and physiotherapy.4,5 Surgical interven-
tion might be considered when non-invasive therapeutic modalities 
fail. DD with reduction (DDwR) describes a displaced disc that re-
duces to a normal position during mouth opening and displaces again 
on closing.6 DD without reduction (DDwoR) refers to a displaced 
disc that does not reduce during mouth opening.6 It has been rec-
ognised earlier that DDwR has a much lower grade of inflammation 
and less joint degeneration compared to DDwoR.7,8 DDwoR may 
present with two different types of onset, either sudden without 
previous symptoms from the joint or delayed, preceded by a longer 
period of clicking and intermittent locking before developing into 
DDwoR.7,9 It can be hypothesised that these two onsets may repre-
sent different entities with different tissue characteristics.
Biomarkers are used to diagnose diseases but also to screen dis-
ease activity and treatment response.10 TMJ synovial fluid has been 
investigated in TMJ patient cohorts and healthy controls.11,12 The 
focus has mainly been cytokines with pro-inflammatory or anti-in-
flammatory properties. Synovial fluid may contain both locally and 
distantly produced cytokines, and thereby indirectly reflect TMJ 
synovial tissue activity. Although sparsely investigated in the TMJ, 
synovial tissue might therefore be a valid complement.10,13 To date, 
no broad investigations of TMJ synovial tissue cytokine profile have 
been performed. Immunohistochemical studies exist but do not 
allow quantification of cytokine concentrations.14-17
The aim of the present study was to characterise and quantify 
synovial tissue cytokines and relate the result to the diagnoses 
DDwR and DDwoR. A secondary aim was to investigate possible dif-
ferences between the subgroup divisions of DDwoR, sudden onset 
(SO) and delayed onset (DO). Characterising a biomarker panel for 
particular conditions may serve as future putative targets for novel 
treatment options.
2  | MATERIAL AND METHODS
2.1 | Study design
This prospective cohort observational study was conducted at the 
Department of Craniofacial Diseases, Karolinska University Hospital, 
Stockholm, Sweden. The Regional Ethics Review Board authorised 
the study (registration number: 2014/622-31/1). Eligible patients 
were those referred because of symptomatic DDwR or DDwoR dur-
ing the period December 2014 to January 2017. Written informed 
consent was collected prior to inclusion. Patients with DDwR were 
used as controls because of anticipated low-grade inflammation, as 
ethical considerations framed us from including TMJ asymptomatic 
patients.7,8 The study was designed and the article written in accord-
ance with the STROBE statement.
2.2 | Study population
A power calculation, based on earlier findings of differences in 
synovial fluid IL-6 concentration between patients with DDwR or 
DDwoR, was made.8 A power of 80% and P = .05 was reached with 
23 patients in the DDwR group and 46 in the DDwoR group. A cal-
culated dropout rate of 10% gave 25 and 51 patients, respectively.
Diagnoses were set according to the Diagnostic Criteria for 
Temporomandibular Disorders (DC/TMD) (Schiffman et al. 2014). 
Criteria for surgery were as follows: DDwR or DDwoR, non-invasive 
therapy tried for at least 3-6 months, visual analogue scale (VAS) 
value of ≥ 4 for TMJ functional pain or TMJ disability, and DDwoR pa-
tients had to have a maximum interincisal opening (MIO) of ≤ 35 mm. 
A subdivision of the diagnosis DDwoR was made. Patients with no 
TMJ symptoms before initiation of DDwoR were categorised as hav-
ing a sudden onset (DDwoR-SO). A history of long-term clicking and/
or intermittent locking before developing DDwoR were considered 
as having delayed onset (DDwoR-DO). Exclusion criteria were prior 
open joint surgery, patient unable to give informed consent and age 
under 18 years.
2.3 | Clinical examination
A standardised case record form was used for collecting patient-
specific data. Surgeons at the department (M.U, A.N-A, C.K-W, B.L), 
calibrated in patient classification and clinical examination, per-
formed patient inclusion and data gathering. Patients were asked for 
present illnesses, medication, ongoing tinnitus/ear fullness affected 
side and duration of present TMJ symptoms. Prior jaw trauma (yes/
no) was registered if the trauma occurred before developing TMJ 
symptoms. MIO, lateral excursion, protrusion, palpation tenderness 
of the masticatory muscles and the TMJ were recorded according to 
DC/TMD.6 TMJ symptoms of pain, disability and psychosocial im-
pact were graded on a 0-10 graded VAS by the patients.18 Wilkes 
classification was preceded by an initial calibration exercise thereaf-
ter performed individually by two of the researchers (M.U and B.L).7 
In case of divergent values, consensus was achieved after discussion.
2.4 | Surgical procedure and collection of 
tissue samples
Surgical interventions were performed under general anaesthesia, 
and the national guidelines for TMJ surgery were followed.19 Patients 
with DDwoR had arthroscopic lysis and lavage, and discectomy was 
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undertaken on patients with DDwR. No prophylactic antibiotic was 
given. Two synovial tissue biopsies were harvested from the supe-
rior part of the posterior bilaminar zone in close proximity to the 
disc attachment. During arthroscopy, synovial biopsies were taken 
under direct visualisation using the triangulation technique in order 
to verify the localisation of the sample.20 Biopsy forceps (Karl Storz 
SE & Co) were used resulting in tissue samples of approximately 
4 mm2. The samples for protein extraction were immediately placed 
in RNAlater (Thermo Fisher Scientific) and refrigerated for 24 hours, 
prior to its removal and sample storage at −80°C. The second bi-
opsy was fixed in 4% paraformaldehyde and paraffin-embedded, 
prior to sectioning and staining with haematoxylin and eosin (H&E, 
Histolab Products AB, Gothenburg, Sweden) for routine histology 
examination.
2.5 | Analysis of synovial tissue
Synovial tissue was weighed and washed twice in ice-cold phos-
phate-buffered saline (PBS) without calcium (Thermo Fisher 
Scientific) prior to grinding in liquid nitrogen to disrupt the tis-
sue piece. Proteins were extracted in ice-cold cell lysis buffer 
with 1mM NP-40 (Thermo Fisher Scientific), containing phenyl-
methanesulphonyl fluoride (PMSF) (Sigma-Aldrich) prepared in 
0.3 mol/L dimethylsulphoxide (DMSO) and protease inhibitor 
cocktail (Sigma-Aldrich).21 50 µL cell lysis buffer per 10 mg of tis-
sue was used and the tissues ground on ice until only white fi-
brous connective tissue remained. The mixtures were centrifuged 
at 20 000 g at 4°C for 10 minutes, and the supernatant stored at 
−80°C until analysis.
The total protein concentration was determined with the Qubit 
Fluorometer (Thermo Fisher Scientific) using the Qubit Protein 
Assay Kit (Thermo Fisher Scientific). Specific proteins were de-
tected with multi-analytic profiling using a Luminex 200 system 
(Luminex) with xMAP technology. Resulting data were analysed by 
the xPONENT 3.1 software (Luminex). Two immunoassays, Human 
Cytokine/Chemokine Magnetic Bead Panel (HCYTOMAG-60K 
[Merck Millipore]) and Human Magnetic Luminex Assay 20-plex 
(LXSAHM-20 [R&D Systems]), were used to determine protein 
levels of bone morphogenetic protein (BMP) 2, BMP 4, BMP 9, 
epidermal growth factor (EGF), eotaxin, fibroblast growth factor 
(FGF) 2, granulocyte-colony stimulating factor (G-CSF), granulo-
cyte-macrophage (GM) CSF, interleukin (IL) 1β, IL-1 receptor an-
tagonist (IL-1ra), IL-6, IL-7, IL-8, IL-10, interferon gamma-induced 
protein (IP) 10, IL-17, monocyte chemoattractant protein (MCP) 1, 
macrophage inflammatory protein (MIP) 1α, MIP-1β, osteoprote-
gerin (OPG), platelet-derived growth factor (PDGF) AA, PDGF-AB/
BB, RANTES, transforming growth factor (TGF) α, tumour necrosis 
factor (TNF) α, TNF-β, triggering receptor expressed on myeloid 
cells (TREM) 1 and vascular endothelial growth factor (VEGF). 
The investigated cytokines were chosen based on earlier stud-
ies on TMJ synovial fluid and tissue as well as studies on other 
joints.8,10-12
2.6 | Statistical analyses
Data were analysed with Stata version 15 (StataCorp) and IBM SPSS 
version 25.0 (IBM Corp). Specific protein concentrations were nor-
malised to the total protein concentration, that is normalised ratio, 
and used in the statistical analysis, as well as the specified protein 
concentrations separately. Descriptive statistics were calculated as 
mean ± SD for all continuous data and as number, and percentage for 
bivariate data. Data on patient characteristics were analysed with 
Student's t test for continuous data and Fisher's exact test for cat-
egorical data. Protein concentrations were not normally distributed 
why median, using quantile regression, was analysed. The model to 
predict the median protein concentration included the diagnoses 
(DDwoR/DDwR or DDwoR-DO/DDwoR-SO) in the unadjusted anal-
yses. The adjusted analyses also included sex and previous trauma as 
dichotomous variables, and age in years and duration of symptoms in 
months as continuous variables. In the adjusted model, missing data 
regarding TMJ trauma (n = 1) and duration (n = 3) were replaced by 
the most common value for trauma and the median value for dura-
tion. The P-values were based on 20 bootstrap samples, and a P-
value of ≤ .05 was regarded as significant.
3  | RESULTS
3.1 | Patient demographics
Patients eligible for inclusion in the study and reasons for not par-
ticipating or being excluded are displayed in Figure 1. In all but four 
patients, biopsies from the synovial tissue were possible to harvest. 
When the study closed, 63 patients had completed the protocol. 
Patient cohort characteristics are shown in Table 1. Symptom du-
ration was significantly longer in patients with DDwR compared to 
DDwoR (P = .008), and as expected, DDwoR had significantly smaller 
MIO (P = .000). DDwoR had significantly higher subjective TMJ 
functional pain score (P = .019) and higher Wilkes criteria (P = .000), 
the latter reflected in the operative features (Figure 2A,B). Subgroup 
analyses performed on DDwoR-DO and DDwoR-SO, revealed that 
pre-operative trauma affected significantly more patients in the SO 
group (P = .024). None of the other patient variables were signifi-
cantly different.
3.2 | Synovial tissue analysis
Histologically, DDwoR tissues presented with mild inflammation, 
whereas little or no inflammation was observed with DDwR tissues 
(Figure 2C,D). Nevertheless, patients with DDwR reported on TMJ 
pain, which might be explained by more pronounced inflammation 
in the joint capsule, masticatory muscles or similar, when no or small 
signs of inflammation in the synovium were present. Furthermore, 
in similarity to previous studies degenerative tissue changes were 
apparent in DDwoR tissues.18
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In the multi-plex protein analysis of the tissue preparations, some 
cytokine concentrations were identified to be below the lowest 
standard (<3.2 pg/mL). These were set at 3.2 pg/mL, whereas values 
above the highest standard (10 000 pg/mL) were set at 10 000 pg/
mL. Samples with cytokine measurements outside of the precision 
and recovery of the assays had no values indicated and were con-
sequently regarded as missing values. The number of tissue samples 
with detectable levels of the specific protein concentration in each 
group is indicated in Table 2. The statistical outcome was compa-
rable when separately using normalised ratio or specified protein 
concentration.
In patients with DDwR, the median total protein concentration 
was 11.80 mg/mL (min 8.19, max 19.60, SD 2.43) and in DDwoR 
15.65 mg/mL (min 3.47, max 44.86, SD 9.49). The difference in total 
protein concentration between the two diagnoses was not significant 
in a multivariate quantile regression analysis, but the variable trauma 
was correlated with a higher total protein concentration (coef. 2.73; 
P = .021; 95% CI 0.44, 5.03). Sex, age and duration of TMJ symptoms 
were included in the analysis but showed no significance.
All analysed cytokines and comparison of measured concentra-
tions between DDwoR and DDwR are shown in Table 2. All detected 
proteins were then analysed in a multivariate regression model 
(Table 3), where possible confounders of sex, age, duration of TMJ 
symptoms and previous TMJ trauma were included. In the adjusted 
model, DDwoR showed significantly higher concentrations of BMP-
2, BMP-4, EGF, eotaxin, G-CSF, IL-1β, IL-7, IL-8, IL-10, MIP-1β, TNF-α 
and TNF-β, and significantly lower concentrations of IP-10, OPG and 
RANTES. The variables age and TMJ trauma had no significant cor-
relation with any of the cytokines.
An unadjusted subgroup analysis of DDwoR-DO and DDwoR-SO 
was made and DO was set as the reference. A significant concentra-
tion difference was found regarding some protein concentrations: 
BMP-2 (coef. 253.9; P = .016; 95% CI 49.7, 458.1), BMP-4 (coef. 
342.2; P = .026; 95% CI 43.4, 641.0), TNF-α (coef. 4.6; P = .000; 
95% CI 2.2, 7.0) and TNF-β (coef. 2.7; P = .047; 95% CI 0.0, 5.4). 
When performing an adjusted analysis with the variables sex, age, 
duration of TMJ symptoms and previous trauma, DDwoR-SO had 
significantly higher concentrations of BMP-4 (coef. 401.2; P = .004; 
95% CI 133.5, 668.8), eotaxin (coef. 137.2; P = .032; 95% CI 12.7, 
261.7) and IL-8 (coef. 14.4; P = .014; 95% CI 3.1, 25.7) compared to 
DDwoR-DO. Trauma was found to have significant relationship with 
lower concentration of PDGF-AA (coef. −131.1; P = .015; 95% CI 
−235.6, −26.5). No significant differences were shown for the vari-
ables sex, age, or TMJ symptom duration.
F I G U R E  1   Flow chart illustrating 
patients eligible for inclusion and reasons 
for not participating. DDwoR, disc 
displacement without reduction; DDwR, 
disc displacement with reduction; DO, 
delayed onset; n, number; SO, sudden 
onset; ST, synovial tissue
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4  | DISCUSSION
A cohort of patients diagnosed with DDwoR or DDwR has been 
compared to evaluate differences in synovial tissue concentration 
for a number of cytokines, in order to describe potential discrepan-
cies between the two diagnoses. TMJ synovial tissue has not been 
investigated in this fashion earlier, and the broad panel of cytokines 
examined also distinguishes this study from earlier synovial fluid and 
tissue analyses, and potentially highlights putative biomarkers.
Patient characteristics revealed that the diagnosis groups were 
homogenous across most variables albeit with some exceptions. 
Patients with DDwoR had significantly higher TMJ pain score and 
Wilkes classification but shorter duration of TMJ symptoms. The 
latter might be explained in that more intense pain potentially in-
duces patients to seek health care earlier. Overall, total protein 
content was significantly higher amongst DDwoR, which was not 
unexpected considering this group exhibited more pronounced TMJ 
pathology, both clinically and radiographically, and it was reflected 
in Wilkes classification.7
Concentrations of 15 out of 28 cytokines were significantly dif-
ferent comparing DDwoR to DDwR patient groups. BMP-2, BMP-
4, EGF, eotaxin, G-CSF, IL-1β, IL-7, IL-8, IL-10, MIP-1β, TNF-α and 
TNF-β were all significantly elevated in DDwoR patients compared 
to DDwR. These multi-functional cytokines may stimulate bone and 
cartilage formation as a result of osteoblast activation, whilst others 
promote osteoclast activity, block chondrocyte function and con-
tribute to tissue damage.22-24 Thus, the observed cytokine variations 
correspond to the tissue degeneration and/or remodelling discerned 
between these patient groups. The majority of elevated cytokines 
were pro-inflammatory, with chemotactic activity recruiting neutro-
phils, granulocytes and lymphoid cells to sites of inflammation.22-28 
In particular, IL-7, EGF and G-CSF initiate tissue responses, to recruit 
and regulate hematopoietic stem cells from bone marrow to differ-
entiate into inflammatory cells.29-31 Furthermore, these cytokines 
TA B L E  1   Pre-operative registration of demographic data, anamnestic information, objective and subjective measurements of included 
patients
Classification DDwoR total DDwoR-SO DDwoR-DO DDwR Total
Demographic data
Number of patients 44 17 27 19 63
Sex, W/M 37/7 13/4 24/3 14/5 51/12
Age (y), mean (SD) 43.0 (16.0) 46.1 (13.0) 41.0 (17.6) 37.3 (12.0) 41.3 (15.1)
Patient history
Durationa  (mo), mean (SD) 21.1 (24.8) 15.9 (8.3) 24.3 (30.4) 44.7 (41.2) 27.8 (31.8)
Tinnitus/ear fullness, n (%) 12 (27) 4 (24) 8 (30) 5 (26) 17 (27)
TMJ trauma, n (%) 10 (23) 7 (41) 3 (11) 7 (37) 17 (27)
Medical history, n (%)
Healthy 18 (41) 8 (47) 10 (37) 10 (53) 28 (44)
Psychiatric disorder 14 (32) 3 (18) 11 (41) 3 (16) 17 (27)
Neuropsychiatric disorder 1 (2) 0 (0) 1 (4) 1 (5) 2 (3)
Autoimmune disease 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Metabolic disease 6 (14) 3 (18) 3 (11) 2 (11) 8 (13)
Other disease 19 (43) 7 (41) 12 (44) 6 (32) 25 (40)
Objective measures
GJH, n (%) 9 (21) 3 (18) 6 (22) 6 (32) 15 (24)
MIO, mm (SD) 29.2 (4.8) 28.6 (5.6) 29.6 (4.2) 43.6 (9.9) 33.6 (9.4)
Wilkes (1-5), mean (SD) 3.9 (0.6) 4.0 (0.7) 3.9 (0.5) 2.5 (0.9) 3.5 (0.9)
Subjective measures mean VAS 
0-10 (SD)
TMJ pain 5.7 (2.4) 6.0 (2.8) 5.5 (2.1) 4.1 (2.4) 5.2 (2.5)
TMJ disability 6.3 (1.7) 6.7 (1.8) 6.0 (1.6) 6.2 (2.0) 6.2 (1.8)
TMJ psychosocialb  3.6 (2.7) 4.4 (2.6) 3.2 (2.7) 5.0 (3.3) 4.0 (2.9)
Global pain 2.7 (2.8) 3.4 (3.4) 2.3 (2.4) 3.0 (3.2) 2.8 (2.9)
Abbreviations: DDwoR, disc displacement without reduction; DDwR, disc displacement with reduction; DO, delayed onset; GJH, general joint 
hypermobility; M, men; MIO, maximum interincisal opening; mo, months; SD, standard deviation; SO, sudden onset; TMJ, temporomandibular joint; 
VAS, visual analogue scale; W, women.
aDuration refers to duration of TMJ symptoms. 
bTMJ psychosocial refers to the psychosocial influence of TMJ problems. 
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may increase endothelial permeability, promoting chemotaxis of 
inflammatory cells and stimulation of angiogenesis.22,23,26,27,32 
Interestingly, IL-1β, IL-8, IL-10 and TNF-α are suggested to be trig-
gered by lipopolysaccharides and infections,22,28,32,33 and it has 
been suggested that an infectious genesis could apply to TMJ dis-
ease,34,35 whilst others have not been able to confirm this.36,37 
DDwoR patients had significantly higher subjective pain scores, 
which corresponded to the increased occurrence of pro-inflamma-
tory cytokines, including IL-1β associated with hyperalgesia, com-
pared to DDwR patients.22
An interesting finding was the significantly lower concentrations 
of IP-10 and RANTES observed amongst DDwoR patients compared 
to DDwR. These two cytokines have been found in higher concen-
trations in chronic inflammatory diseases, like rheumatoid arthritis, 
correlated to enhanced bone and chondral resorption, leucocyte 
recruitment, angiogenesis and fibrosis.10,22,27 These earlier find-
ings indicate that IP-10 and RANTES should have had higher con-
centrations in DDwoR compared to DDwR, which obviously is not 
the case in this investigation. The concentration of OPG, known as 
a bone-protecting protein, was also significantly lower in DDwoR, 
which might indicate an interaction between OPG and IP-10 and 
RANTES in DDwoR bone turnover homoeostasis.38 The finding of 
lower concentrations of IP-10, OPG and RANTES in DDwoR might 
perhaps suggest a different disease activity compared to both 
DDwR and to chronic inflammatory arthritis (CIA), as higher lev-
els could have been anticipated.10,27,38 Bilateral affection of TMJ is 
common in CIA, which is rarely the case in DDwoR. In the current 
study, only two cases were bilaterally affected why meaningful sta-
tistical evaluation was not possible. However, a daring suggestion 
might be that bilateral cases could advocate the clinician to further 
investigate different aetiologies, like CIA. OPG, IP-10 and RANTES 
might eventually serve as biomarkers to aid diagnosis and guide to 
alternative treatment options before scheduling surgery. All cyto-
kines shown to have significantly divergent concentrations might be 
useful biomarkers in the complex cytokine inflammatory response 
to TMJ disorder and warrants further confirmatory investigations.
Both EGF and IL-1ra presented with significantly higher con-
centrations amongst women. Previously, it has been recognised 
that EGF has a sexual dimorphism, with higher levels in women’s 
urine and kidneys.30 Considering the strong female predominance 
amongst DD patients, the significance of these findings should be 
addressed in future studies. The presence of OPG also strongly cor-
related with an extended duration of symptoms, indicating that os-
teoclast inhibition may increase with time.38
DDwoR-SO was shown to have significantly higher concentra-
tions of BMP-4, eotaxin and IL-8 compared to DDwoR-DO. BMP-4 
promotes bone and chondral repair whilst eotaxin is upregulated 
during bone inflammation increasing osteoclast activity.23,24 IL-8, 
known as a potent chemokine, stimulates phagocytosis and poten-
tially may be the regulator of inflammatory-driven bone turnover, 
which requires increased numbers of scavenger cells.28 Furthermore, 
healing may be impaired in DDwoR patients since PDGF-AA con-
centration showed negative correlation with previous trauma.39 
However, the limited cohort of only 44 patients must moderate 
these bold suggestions of cytokine context in DDwoR.
Synovial fluid analyses have suggested differences in cyto-
kine concentrations in healthy controls compared to patients with 
DD.12 Harvesting of intra-articular tissue is considered an invasive 
procedure and ethical considerations refrained us from including 
healthy controls. Patients with DDwR were used as substitutes to 
healthy controls because of earlier reports on low-grade inflam-
mation.7,8 From this perspective, there are limitations in inter-
pretation of the cytokines’ concentration. The current selection 
of analysed cytokines was based on previous investigations, but 
F I G U R E  2   Histologically stained 
synovial tissues (scale bar 100 µm) and 
intra-articular photographs from the 
superior joint compartment. A, Patient 
with DDwoR showing a fibrotic adhesion 
between the articular tubercle and the 
disc. Synovial creeping covering part 
of the articular tubercle illustrating 
inflammation. B, DDwR with mild capillary 
hyperaemia affecting the posterior 
bilaminar zone and a minor area with signs 
of cartilage breakdown. C, Representative 
H&E-stained image of DDwoR tissue. D, 
H&E-stained representative DDwR image
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TA B L E  2   Concentration of cytokines in DDwoR and DDwR and an unadjusted quantile regression analysis comparing median cytokine 




DDwoR/DDwR (pg/mL) Quantile regressionb 
Min-max Median (SD) Coef. P 95% CI
BMP 2 44 67.1-1659.4 399.9 (349.2) −331.9 .000 −487.5 −176.3
19 66.4-169.2 70.8 (31.5)
BMP 4 44 70.8-2550.2 540.8 (531.5) −439.8 .000 −610.1 −269.5
19 101.3-243.1 105.0 (31.7)
BMP 9 5 0.6-312.0 120.6 (154.0) −117.4 .510 −492.1 257.3
10 0.3-568.4 2.8 (178.8)
EGF 44 9.5-160.0 56.8 (36.8) −30.4 .014 −54.3 −6.4
19 7.1-137.4 26.8 (36.6)
Eotaxin 44 14.0-586.0 113.5 (142.9) −86.5 .000 −130.7 −42.3
19 4.6-76.8 30.2 (19.3)
FGF2 44 1157.6-37281.5 10616.3 (7292.3) 1430.9 .441 −2257.0 5118.9
19 5666.4-22374.1 12296.9 (3615.5)
G-CSF 44 5.6-1675.5 273.7 (396.9) −229.8 .001 −361.6 −98.0
19 1.0-2011.7 43.9 (452.4)
IL-1β 40 0.1-20.4 1.7 (4.3) −1.3 .004 −2.2 −0.4
18 0.1-3.1 0.5 (0.7)
IL-1ra 44 6.9-208.7 51.9 (49.9) −16.7 .456 −61.3 27.9
19 1.4-614.0 36.4 (138.5)
IL-6 11 1.0-83.9 10.3 (24.2) −5.8 .541 −25.4 13.8
7 1.4-7.8 4.5 (2.7)
IL-7 44 1.8-283.0 44.6 (68.0) −31.0 .000 −43.8 −18.2
19 4.2-134.4 15.3 (28.1)
IL-8 44 0.9-85.9 26.2 (20.5) −20.6 .000 −30.0 −11.1
19 2.8-35.6 5.9 (7.0)
IL-10 43 0.2-41.3 8.1 (9.1) −4.7 .000 −7.2 −2.2
19 0.2-10.8 2.5 (2.5)
IP-10 44 9.6-5806.2 91.6 (877.7) 172.9 .000 88.6 257.3
19 62.6-1338.7 268.9 (335.0)
MCP-1 44 10.5-1608.6 331.4 (380.9) −105.0 .472 −395.2 185.2
19 127.2-4979.9 243.7 (1289.1)
MIP-1α 16 2.5-104.9 13.4 (31.5) −10.4 .212 −27.2 6.4
10 0.8-14.9 3.1 (5.2)
MIP-1β 17 3.2-127.0 20.8 (32.3) −11.8 .159 −28.5 4.9
14 1.8-40.3 8.4 (9.6)
OPG 44 150.9-61073.2 2997.6 (10370.6) 2551.1 0.661 −9035.8 14137.9
19 1278.0-202633.2 5900.0 (46094.3)
PDGF-AA 44 23.9-2429.6 138.4 (416.2) 170.1 .021 26.0 314.2
19 108.2-822.0 313.3 (221.6)
PDGF-AB/
BB
44 20.6-20159.9 663.4 (3129.1) 1566.0 .190 −795.3 3927.3
19 482.1-21388.6 2264.3 (5070.6)
RANTES 44 372.3-34905.2 3683.4 (8172.4) 6677.7 .021 1036.7 12318.6
19 4312.9-30000.0 10627.5 (6029.7)
TNF-α 44 0.8-21.4 4.5 (4.9) −2.5 .000 −3.5 −1.4
19 1.2-7.0 2.1 (1.4)
(Continues)




DDwoR/DDwR (pg/mL) Quantile regressionb 
Min-max Median (SD) Coef. P 95% CI
TNF-β 34 0.5-22.0 2.7 (4.1) −2.0 .018 −3.7 −0.4
18 0.3-5.6 0.7 (1.4)
TREM-1 35 13.6-5264.0 360.6 (981.6) −193.0 .247 −523.4 137.4
19 36.3-3299.9 167.6 (727.9)
VEGF 44 9.6-983.8 60.0 (192.2) −6.3 .858 −77.0 64.3
19 9.6-1398.4 53.7 (382.6)
GM-CSFc  7 0.8-8.1 1.4 (2.7)
6 0.5-5.1 1.9 (1.6)
IL-17c  4 3.7-7.7 5.3 (1.8)
0 - -
TGF-αc  3 0.2-4.2 0.4 (2.3)
4 1.2-72.2 2.3 (35.1)
Abbreviations: CI, confidence interval; DDwoR, disc displacement without reduction; DDwR, disc displacement with reduction; mL, millilitre; pg, 
picogram; SD, standard deviation.
aNumber of synovial tissue samples with detected levels of the specified protein concentration. 
bThe quantile regression was modelled from DDwoR, and the coefficient thereby shows if DDwR has a lower (negative coef.) or higher (positive coef.) 
median concentration. 
cQuantile regression was not possible because there were too few samples with detectable protein concentrations. 
TA B L E  2   (Continued)
TA B L E  3   Quantile regression of cytokine concentrations in DDwoR and DDwR, adjusted for the variables sex, age, duration of TMJ 
symptoms and previous trauma
Variables DDwoR vs DDwRa  Sexb  Duration
Protein Coef. 95% CI Coef. 95% CI Coef. 95% CI
BMP2 −326.0** −470.8 −181.3 −8.3 −114.5 97.8 −0.0 −1.2 1.2
BMP4 −439.9* −780.2 −99.5 −0.5 −235.3 234.3 0.0 −4.9 4.9
EGF −20.9* −40.1 −1.7 23.2* 2.1 44.3 0.1 −0.3 0.4
Eotaxin −83.8** −120.0 −47.6 −14.7 −73.1 43.8 −0.0 −0.7 0.6
G-CSF −226.5** −331.7 −121.2 −26.5 −208.6 155.6 0.2 −5.2 5.6
IL-1β −1.3** −2.0 −0.7 0.2 −0.5 0.9 0.0 −0.0 0.0
IL-1ra −13.6 −38.1 10.9 30.8* 3.4 58.3 −0.0 −0.3 0.2
IL-7 −30.8** −50.4 −11.1 8.5 −27.9 45.0 −0.0 −0.2 0.1
IL-8 −19.1** −27.9 −10.4 4.6 −3.2 12.5 −0.0 −0.1 0.0
IL-10 −4.7* −7.8 −1.6 0.0 −4.5 4.5 −0.0 −0.1 0.1
IP-10 178.9** 24.7 333.1 4.9 −96.2 106.1 −0.1 −2.4 2.2
MIP-1β −14.1* −24.1 −4.1 11.8 −2.4 26.0 −0.0 −0.2 0.1
OPG 2230.1* 38.3 4421.9 119.6 −2931.4 3170.6 139.0* 29.1 248.9
RANTES 6548.3** 2876.0 10620.6 2190.2 −1948.2 6328.5 −38.1 −126.7 50.4
TNF-α −2.1** −3.4 −0.7 0.8 −1.2 2.8 −0.0 −0.0 0.0
TNF-β −1.9* −3.5 −0.2 −1.3 −4.5 1.9 −0.0 −0.0 0.0
Note: Only cytokines and variables with significant results are included in the table.
Abbreviations: CI, confidence interval; DDwoR, disc displacement without reduction; DDwR, disc displacement with reduction.
aThe quantile regression was modelled from DDwoR, and the coefficient thereby shows if DDwR has a lower (negative coef.) or higher (positive coef.) 
median concentration. 
bMale gender was modelled as the reference. 
*P < .05. 
**P < .005. 
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several cytokines, such as IFN-γ and TGF-β, were not included, 
further limiting the study. Additional studies with analysis of a 
broader panel of cytokines, together with in vitro studies on cyto-
kine interaction, are required to elucidate the specific mechanisms 
of inflammation in DD and to deepen the understanding of the 
pathogenesis.
The generalisability of the study cohort results is considered 
fairly good considering the well-defined inclusion criteria and pa-
tient characteristics in combination with power-based study-popu-
lation size. However, one cannot neglect that possible geographical 
or cultural differences may influence the data. In addition, less pro-
nounced individual differences may remain undetected in this lim-
ited cohort.
5  | CONCLUSION
Significant differences in concentrations of synovial tissue ex-
tracted cytokines were found when comparing patients with 
DDwoR to patients with DDwR. IP-10, OPG and RANTES showed 
significantly higher concentrations in DDwR patients, and BMP-2, 
BMP-4, EGF, eotaxin, G-CSF, IL-1β, IL-7, IL-8, IL-10, MIP-1β, TNF-α 
and TNF-β had significantly higher concentrations in DDwoR pa-
tients. EGF and IL-1ra concentrations were significantly higher in 
women compared to men. DDwoR-SO patients had concentrations 
of BMP-4, eotaxin and IL-8 that were significantly higher than in 
DDwoR-DO. The current findings may lead to further insights in 
TMJ disease and form basis for research on biomarkers and novel 
medical treatments.
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